Financial Performance Summary

Quarterly Results (Q1 FY27 ended June 30, 2026)

| Particulars | Q1 FY27 | Q1 FY26 | Growth |

| Revenue from Operations | ₹195.7 Cr | ₹168.9 Cr | 15.8% |

| EBITDA | ₹48.0 Cr | ₹40.7 Cr | 17.9% |

| EBITDA Margin | 24.5% | 24.1% | +40 bps |

Business Segment Performance

Domestic Formulations Business:

  • Grew 14.8% during the quarter
  • Outperformed broader Indian Pharma Market growth of 11.6%
  • Supported by key therapy focus, new product introductions, and field-force effectiveness

International Formulations Business:

  • Registered 7.7% growth during the quarter

API Business:

  • Delivered 35.6% growth during the quarter
  • Growth driven by unit coming back to operations

Key Achievements and Milestones

  • RPG Life Sciences entered the list of Top 50 Indian pharmaceutical companies in June 2026 (Source: Pharmarack MAT June 2026 Database)
  • Company became the 5th fastest growing company in Indian Pharma Market (IPM)
  • Naprosyn grew at 16% this quarter
  • Double-digit growth of key baskets like nephrology and rheumatology
  • Recognized as 'Top Nephrology Company- 2026' by India Pharma Outlook
  • Recognized for 'Best Use of AI in Sales Force Effectiveness' by Bluetech Media
  • Received 'Excellence in Breakthrough Pharmaceutical Innovations' by Network 7 Media

Management Commentary

Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., commented:

  • Company started FY27 on a strong note continuing track record of market-beating performance
  • Domestic Formulations business outperformed the market and helped company enter Top 50 ranking
  • Focus on strengthening international presence through market expansion and new customer onboarding
  • Scaling up API operations to drive next wave of growth
  • Backed by strong balance sheet, healthy profitability, and continued investment in talent
  • Confident of sustaining growth momentum in the long-term

Margin Drivers

EBITDA margin expansion to 24.5% (up 40 bps year-over-year) was achieved through:

  • Operating discipline
  • Strategic launches
  • Field-force effectiveness
  • Key therapy focus

Company Background

RPG Life Sciences is an integrated research-based pharmaceutical company operating in domestic and international markets in branded formulations, global generics, and synthetic APIs space. The company produces a wide range of quality, affordable medicines, with brands highly trusted by healthcare professionals and patients.

RPG Group, established in 1979, is one of India's fastest-growing business groups with a turnover of US$ 5.2 billion, with diverse business interests in Infrastructure, Tyres, Pharma, IT and Specialty, as well as emerging innovation-led technology businesses.